Transketolase plays a critical role in the replication of SARS-CoV-2 viruses in host cells. Initial studies* have now shown that inhibiting transketolase can prevent the virus from replicating.
Host cells in which viruses multiply are characterized by increased sugar uptake (glucose) and thus become visible on FDG-PET – as do tumor cells.
In their publication, the authors conclude that inhibition of sugar metabolism is a promising target for a future drug.
New Therapeutic Options for
SARS-CoV-2 Infections
New Therapeutic Options for SARS-CoV-2 Infections
Our goal
We see great opportunities to develop an effective drug against COVID-19 (independent of possible viral mutations). For its research, benfovir AG uses an active ingredient that inhibits sugar metabolism in a way that prevents the generation of the crucial building block for virus formation (ribose-5-phosphate), while also avoiding an overreaction of the immune system.
Where We Are At
In recent months, all preclinical studies have been completed successfully. This means that the prerequisites for conducting the first clinical studies have been met. Discussions with the responsible authorities are underway to obtain the necessary approvals.
Next Steps
Our next goal is to now start the clinical phases in order to obtain marketing approval and establish a new therapeutic option for SARS-CoV-2 infections and COVID-19 disease as soon as possible.
Why we inhibit sugar metabolism and Ribose-5-Phosphate
Increased Sugar Requirement of Host Cells
Background
Persons with elevated blood glucose are among those at risk for a severe clinical course if they develop COVID-19.
Press Release
benfovir AG. June 1st, 2022
benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT
B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS
benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers.
benfovir AG. June 1st, 2022
benfovir Announces First Subjects Dosed in Phase 1 Clinical Trial of B-OT
B-OT IS BEING DEVELOPED FOR THE TREATMENT OF VIRAL INFECTIONS
benfovir AG has reached another major milestone by moving its first compound into clinical development with the start of a Phase 1 testing B-OT in healthy volunteers.
benfovir AG, December 10th, 2021
New therapeutic approach against SARSCoV-2 successfully tested
Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARSCoV- 2 virus in human cells. The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells.
benfovir AG, December 10th, 2021
New therapeutic approach against SARSCoV-2 successfully tested
Scientists at the Universities of Frankfurt a.M. and Kent (UK) have identified a metabolic pathway (pentose-phosphate pathway) that is crucial for the propagation of the SARSCoV- 2 virus in human cells. The compound benfo-oxythiamine, an inhibitor of this metabolic pathway, has succeeded in blocking the replication of the SARS-CoV-2 virus in human cells.
Partners Wanted
Do you have questions, are you interested in our clinical studies or would you like to participate in the further development of the inhibitor? Please contact us!
